LONG BEACH, Calif. — In this video from the American Society of Retina Specialists annual meeting, Charles C. Wykoff, MD, PhD, FASRS, discusses sozinibercept combination therapy in the phase 3 ShORe and COAST trials.

The primary endpoint was not met in either study, which combined sozinibercept (Opthea) with ranibizumab or aflibercept for the treatment of neovascular age-related macular degeneration.

“This was a robust phase 3 clinical trial program involving nearly 2,000 patients,” Wykoff, of Retina Consultants of Texas, told Healio. “In this program, sozinibercept in combination with aflibercept or ranibizumab did not improve visual or anatomic outcomes in neovascular AMD management compared to either aflibercept or ranibizumab alone.”

See Full Page